The BD Onclarity™ HPV Assay includes genotype reporting beyond HPV genotypes 16, 18, and 45 to include types 31, 51, 52, 33/58, 35/39/68 and 56/59/66. The BD Onclarity™ HPV Assay detects and identifies 14 high-risk human papillomavirus (HPV) types in a single analysis and provides genotyping information from specimens collected for cervical cancer screening purposes. Current estimates indicate that every year in Europe, more than 61,000 women are diagnosed with cervical cancer and nearly 26,000 die from the disease, iv making cervical cancer the second-most common female cancer deaths in women aged 15 to 44 and the ninth-most frequent cancer among women overall. Persistent infection with HPV is the cause of virtually all cases of cervical cancer iii. Over half of all cervical cancers are diagnosed in women who have never been screened or have not been screened in the previous five years ii, a situation that has been compounded by the recent global pandemic. "Not only does self-collection afford women greater access to testing, but they may also feel confident that the reliability of HPV testing of self-collected samples is the same as if they went to a clinician i."Īt-home collection will help address the urgent public health challenge of reaching women who do not attend routine cervical cancer screening. Jeff Andrews, vice president of Global Medical Affairs at BD. "The goal of cervical cancer screening is simple but critical: to detect pre-cancer before it develops into cancer," stated Dr. BD Onclarity™ HPV Assay 3-Well PCR Reagent Wells
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |